液体肿瘤生物指标检测对乳腺癌患者的临床价值  

The clinical value of liquid tumor biomarker detection for breast cancer

作　　者：周金妹[1] 江泽飞[1] 

机构地区：[1]军事医学科学院附属医院乳腺肿瘤内科,北京100071

出　　处：《中国癌症杂志》2014年第8期636-640,共5页China Oncology

摘　　要：循环肿瘤标志物在乳腺癌中的应用受到越来越多的关注,研究水平已从蛋白质水平深入到基因水平,相应的检测指标则从传统的肿瘤标志物扩展到相对特异的HER-2蛋白质细胞外段、循环肿瘤细胞、循环肿瘤DNA及循环RNA等。作为"液体检测",循环肿瘤标志物的检测因其实时动态、操作简便、可重复性好等优势,被广泛应用于协助早期诊断、判断预后、预测疗效、监测疾病复发及病情变化等方面。对循环肿瘤标志物的深入研究,有助于实现患者的个体化治疗。Circulating tumor markers have been paid more attention in the application of the treatment for breast cancer, the level of which has extended from protein to gene, including traditional tumor markers, HER-2 extracellular domain, circulating tumor cells, circulating tumor DNA （ctDNA）, circulating RNA （ctRNA） and so on. As “liquid detection”, the detection of circulating tumor markers with real-time dynamic, easy operation, good reproducibility and other advantages are widely used in aiding early diagnosis, determining prognosis, prospectively predicting response or resistance to speciifc therapies, surveillance after primary surgery, and monitoring therapy in patients with advanced disease, The further study of circulating tumor markers may contribute to patient’s individual treatment.

关 键 词：乳腺癌 CA15—3 CEA 蛋白质细胞外段 循环肿瘤细胞 循环肿瘤DNA 循环肿瘤RNA 

分 类 号：R737.9[医药卫生—肿瘤]